AI Drug-Discovery made in days, not decades
SynAgentics Biosciences is developing an agentic AI-driven drug discovery platform that connects scientific reasoning, computational tools, and evidence-based decision-making into one structured workflow.
4.8×
faster hit triage
92%
assay evidence coverage
11
active lead programs
Platform
One intelligence layer for every discovery decision.
SynAgentics connects biological rationale, chemical design, and translational risk into a single ranked operating system for drug programs.
Biology graph
Target discovery
Rank disease mechanisms from literature, omics, perturbation screens, and pathway-level causal evidence.
Chemistry model
Generative design
Explore novel matter with property constraints, synthesis feasibility, and selectivity goals optimized together.
Risk engine
Translational prediction
Prioritize programs with patient stratification, biomarker strength, toxicity signals, and assay confidence.
Evidence ops
Automated review
Continuously monitor new papers, patents, and trial data so investment memos stay current by default.
External Proof-of-Concept
Nature
A multi-agent system for automating scientific discovery
Journal of Chemical Information and Modeling
Cheminformatics Meets Molecular Mechanics
Nature
Towards the end-to-end automation of AI research
Journal of Chemical Information and Modeling
Pose Filter-Based Ensemble Learning Enables Discovery of Orally Active, Nonsteroidal Farnesoid X Receptor Agonists
Workflow
Compress years of search into evidence-ranked cycles.
The platform continuously turns disease context into candidate lists, validation plans, and board-ready program decisions.
01
Map disease biology
Ingest omics, literature, pathway, and trial signals to rank targets by mechanistic plausibility.
02
Generate candidates
Design molecules and biologics against target, safety, novelty, and manufacturability constraints.
03
Validate the lead
Convert predictions into assay plans, partner decisions, and translational evidence packages.
Advance the next lead program before the next board meeting.
SynAgentics is opening partner conversations with biotech teams, venture studios, and strategic pharma groups building AI-first pipelines.